MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.63
-0.11
-1.26%
After Hours: 8.69 +0.06 +0.70% 19:59 03/08 EST
OPEN
8.93
PREV CLOSE
8.74
HIGH
9.29
LOW
8.30
VOLUME
23.85M
TURNOVER
--
52 WEEK HIGH
18.77
52 WEEK LOW
0.1700
MARKET CAP
1.62B
P/E (TTM)
-507.6471
1D
5D
1M
3M
1Y
5Y
Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know
Zacks · 3h ago
Ocugen Inc. to Present at Upcoming March Investor Conferences
MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19...
GlobeNewswire · 6h ago
Seeking Alpha Catalyst Watch
Seeking Alpha's Catalyst Watch for stocks Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events
Seekingalpha · 3d ago
Top Stocks To Invest In Now? 4 Biotech Stocks To Watch
StockMarket.com · 5d ago
FUBO, RKT, TRXC and SOS among midday movers
Gainers: Cohen & Company Inc. (COHN) +109%.Veritiv Corporation (VRTV) +62%.KemPharm, Inc. (KMPH) +36%.Ovid Therapeutics Inc. (OVID) +36%.Super League Gaming, Inc. (SLGG) +35%.MingZhu Logistics Holdings Limited (YGMZ) +32%.Asensus Surgical, Inc. (TRXC)
Seekingalpha · 5d ago
Is Ocugen Stock a Buy Right Now? This Is What You Need to Know
Ocugen (OCGN) is a latecomer to the coronavirus stock party. But in true latecomer fashion, it has made a dazzling entrance. Shares are up year-to-date by 544%, as inv...
TipRanks.com · 5d ago
DJ Ocugen Price Target Raised to $15.00/Share From $4.00 by Cantor Fitzgerald
Dow Jones · 5d ago
DJ Ocugen Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 5d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCGN stock price target is 9.00 with a high estimate of 13.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 20.59M
% Owned: 10.95%
Shares Outstanding: 188.03M
TypeInstitutionsShares
Increased
7
2.55M
New
31
1.30M
Decreased
5
3.15M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Chief Financial Officer/Chief Accounting Officer/Treasurer
Sanjay Subramanian
Senior Vice President
Vijay Tammara
Vice President/Secretary/IR Contact Officer
Kelly Beck
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Manish Potti
Independent Director
Suha Taspolatoglu
Independent Director
Junge Zhang
No Data
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.